Veru/$VERU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veru
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Ticker
$VERU
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
210
ISIN
US92536C1036
Website
Veru Metrics
BasicAdvanced
$96M
-
-$0.25
-0.73
-
Price and volume
Market cap
$96M
Beta
-0.73
52-week high
$1.42
52-week low
$0.45
Average daily volume
2.7M
Financial strength
Current ratio
3.804
Quick ratio
3.491
Long term debt to equity
12.548
Total debt to equity
16.101
Interest coverage (TTM)
-67.46%
Management effectiveness
Return on assets (TTM)
-49.03%
Return on equity (TTM)
-93.86%
Valuation
Price to revenue (TTM)
5.661
Price to book
4.55
Price to tangible book (TTM)
6.76
Price to free cash flow (TTM)
-3.269
Growth
Revenue change (TTM)
134.43%
Earnings per share change (TTM)
-32.24%
3-year revenue growth (CAGR)
-34.64%
3-year earnings per share growth (CAGR)
-10.61%
What the Analysts think about Veru
Analyst ratings (Buy, Hold, Sell) for Veru stock.
Veru Financial Performance
Revenues and expenses
Veru Earnings Performance
Company profitability
Veru News
AllArticlesVideos
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
GlobeNewsWire·1 week ago
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Accesswire·4 weeks ago
Veru Participates in a Virtual Investor KOL Connect Segment
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veru stock?
Veru (VERU) has a market cap of $96M as of June 06, 2025.
What is the P/E ratio for Veru stock?
The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of June 06, 2025.
Does Veru stock pay dividends?
No, Veru (VERU) stock does not pay dividends to its shareholders as of June 06, 2025.
When is the next Veru dividend payment date?
Veru (VERU) stock does not pay dividends to its shareholders.
What is the beta indicator for Veru?
Veru (VERU) has a beta rating of -0.73. This means that it has an inverse relation to market volatility.